Skandinaviska Enskilda Banken AB publ Has $74.92 Million Stock Position in Abbott Laboratories $ABT

Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 51.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 559,321 shares of the healthcare product maker’s stock after purchasing an additional 190,255 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Abbott Laboratories were worth $74,915,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of ABT. SMART Wealth LLC acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth $206,000. Southeast Asset Advisors LLC grew its position in Abbott Laboratories by 69.7% in the third quarter. Southeast Asset Advisors LLC now owns 23,364 shares of the healthcare product maker’s stock valued at $3,129,000 after acquiring an additional 9,600 shares during the last quarter. Summitry LLC raised its stake in Abbott Laboratories by 66.4% during the third quarter. Summitry LLC now owns 2,853 shares of the healthcare product maker’s stock worth $382,000 after acquiring an additional 1,138 shares in the last quarter. M&G PLC bought a new position in shares of Abbott Laboratories in the third quarter worth about $31,851,000. Finally, Zions Bancorporation National Association UT boosted its stake in shares of Abbott Laboratories by 18.7% in the 3rd quarter. Zions Bancorporation National Association UT now owns 5,899 shares of the healthcare product maker’s stock valued at $790,000 after purchasing an additional 928 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The stock was purchased at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Up 1.0%

Shares of ABT opened at $112.63 on Tuesday. The company has a market capitalization of $195.84 billion, a PE ratio of 30.28, a PEG ratio of 1.79 and a beta of 0.75. The stock’s 50-day moving average price is $119.30 and its two-hundred day moving average price is $126.29. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period last year, the company earned $1.34 earnings per share. The firm’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, February 13th. Investors of record on Thursday, January 15th were issued a $0.63 dividend. The ex-dividend date was Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Leerink Partners dropped their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Sanford C. Bernstein lowered their price target on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Royal Bank Of Canada cut their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Oppenheimer lowered their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, The Goldman Sachs Group cut their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $137.05.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.